Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing

The incidence of allergic disease has grown tremendously in the past three generations. While current treatments are effective for some, there is considerable unmet need. Mast cells are critical effectors of allergic inflammation. Their secreted mediators and the receptors for these mediators have l...

Full description

Saved in:
Bibliographic Details
Published inCells (Basel, Switzerland) Vol. 11; no. 19; p. 3031
Main Authors Burchett, Jason R, Dailey, Jordan M, Kee, Sydney A, Pryor, Destiny T, Kotha, Aditya, Kankaria, Roma A, Straus, David B, Ryan, John J
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 27.09.2022
MDPI
Subjects
Allergic reaction
Allergies
Allergy
Anaphylaxis
Asthma
atopy
Autoimmunity
Binding sites
Cell activation
Clinical trials
Cytokines
Dermatitis
Disease
Drug dosages
Drug Repositioning
Drug targeting
Drug therapy
FDA approval
Gene expression
Health aspects
Histamine
Humans
Hypersensitivity
IgE
Immunoglobulin E
Immunoglobulin E - metabolism
Inflammation
Interleukin 13
Interleukin 4
Interleukin-13 - metabolism
Interleukin-4 - metabolism
mast cell
Mast cells
Mast Cells - metabolism
Medical research
Metabolic disorders
Methods
Monoclonal antibodies
repurposing
Review
Urticaria
United States
United States > US
STAT
statin
JAK
inflammation
IgE
atopy
mast cell
repositioning
allergy
repurposing
Online AccessGet full text

Cover

More Information
Summary:The incidence of allergic disease has grown tremendously in the past three generations. While current treatments are effective for some, there is considerable unmet need. Mast cells are critical effectors of allergic inflammation. Their secreted mediators and the receptors for these mediators have long been the target of allergy therapy. Recent drugs have moved a step earlier in mast cell activation, blocking IgE, IL-4, and IL-13 interactions with their receptors. In this review, we summarize the latest therapies targeting mast cells as well as new drugs in clinical trials. In addition, we offer support for repurposing FDA-approved drugs to target mast cells in new ways. With a multitude of highly selective drugs available for cancer, autoimmunity, and metabolic disorders, drug repurposing offers optimism for the future of allergy therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2073-4409
2073-4409
DOI:10.3390/cells11193031